Results 131 to 140 of about 1,998,403 (289)
Klotho deficiency promotes podocyte mitochondrial dysfunction and ferroptosis through activation of the PKCα/CUX1/SPARC/TGFβ‐RII axis. SPARC emerges as a key mediator linking Klotho loss to podocyte injury in DKD and other kidney injury models, suggesting broader implications for CKD progression.
Qing Yang +11 more
wiley +1 more source
A novel PLGA/PBAE polymer microparticle platform revolutionizes intermediate‐stage liver cancer treatment by co‐delivering panobinostat and IL‐12 via a single TACE‐like injection. This sustained‐release system overcomes tumor immunosuppression, triggers robust innate and adaptive immune responses, and establishes tertiary lymphoid structures ...
Hongzhe Yu +7 more
wiley +1 more source
A Transformer‐based AI framework, DLINP, screens millions of compounds to identify Co68, a cobalt‐pincer organometallic complex that biases TLR4‐MD2 signaling toward antitumor interferon activation while suppressing inflammatory toxicity through an early TLR4‐SYK‐STAT1 axis.
Xuefei Guo +10 more
wiley +1 more source
Natural‐Inspired Engineered Microalgae With Selenium Enrichment Enabled Potent Anti‐Tumor Immunity
Se‐Ssp was engineered as a potent immunomodulator for activating innate immunity via the TLR and cGAS‐STING pathways, therefore converting “cold” tumors into “hot” tumors to achieve high efficacy and long‐term therapeutic outcomes. ABSTRACT Immunotherapy has shed light on clinical oncology for several decades.
Yuqi Yang +11 more
wiley +1 more source
Structural basis for the activity and specificity of the immune checkpoint inhibitor lirilumab
The clinical success of immune checkpoint inhibitors has underscored the key role of the immune system in controlling cancer. Current FDA-approved immune checkpoint inhibitors target the regulatory receptor pathways of cytotoxic T-cells to enhance their ...
Nicholas Lorig-Roach +2 more
doaj +1 more source
Tumor cells can utilize the immune checkpoint pathway to inhibit T cell activation and evade the attack of tumor specific T cells. While immune checkpoint inhibitors (ICIs) competitively bind to checkpoint molecules to block checkpoint mediated ...
Jing Chen, Xue Cheng
doaj +1 more source
Herein, an ultrasound‐responsive BiO2‐X/siFn1 nanoplatform is developed to overcome anti‐PD‐1 resistance in hepatocellular carcinoma. Upon ultrasound irradiation, the platform downregulates fibronectin expression, while its sonothermal effect softens the dense extracellular matrix and activates antitumor immunity in the tumor microenvironment, thereby ...
Huimin Tian +10 more
wiley +1 more source
Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook
Dharmesh Gopalakrishnan,1 Vadim S Koshkin,2 Moshe C Ornstein,2 Athanasios Papatsoris,3 Petros Grivas2,4 1Department of Hospital Medicine, Cleveland Clinic, Cleveland, OH, USA; 2Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland ...
Gopalakrishnan D +4 more
core
Successful treatment of immune checkpoint inhibitor-related periaortitis [PDF]
We report a 64-year-old patient with melanoma receiving ipilimumab and nivolumab therapy who presented with a periaortic soft tissue mass around the abdominal aorta on restaging fluorodeoxyglucose positron emission tomography/computed tomography imaging.
Özdemir, Berna C +7 more
core +2 more sources
Chemotherapy leverages tumor‐cell autophagy to reshape the colorectal cancer immune microenvironment. Autophagy degrades FBXW2 to promote C/EBPβ‐mediated TIMP‐2 transcription and MMP‐9 suppression, driving intra‐tumoral CD8+ T‐cell infiltration. Targeting MMP‐2/9 or restoring TIMP‐2 overcomes chemo‐resistance in autophagy‐deficient tumors. ABSTRACT The
Bing Cheng +12 more
wiley +1 more source

